Rabbit Polyclonal GPER1 Antibody

GPER1 (G protein-coupled estrogen receptor 1), also known as GPR30. is a transmembrane receptor that mediates rapid, non-genomic estrogen signaling, distinct from classical nuclear estrogen receptors (ERα/ERβ). Identified in the late 1990s, GPER1 is implicated in diverse physiological and pathological processes, including cancer progression, cardiovascular regulation, and metabolic homeostasis. Antibodies targeting GPER1 are critical tools for studying its expression, localization, and function. These antibodies are typically developed against specific epitopes, such as extracellular or intracellular domains, to facilitate applications like Western blotting, immunohistochemistry, and flow cytometry. However, challenges persist in antibody specificity due to potential cross-reactivity with unrelated proteins or epitope similarities in related receptors. Validation via knockout controls or siRNA silencing is essential to confirm target specificity. GPER1 antibodies have been instrumental in uncovering its role in estrogen-sensitive cancers (e.g., breast, ovarian) and its interaction with signaling pathways like EGFR and MAPK. Recent studies also explore its therapeutic potential in cardiovascular and neurodegenerative diseases. Despite progress, variability in antibody performance across commercial sources underscores the need for standardized validation protocols to ensure reproducibility in research findings.